Continuous retinal vessel diameter m easurements: the future in retinal vessel assessment? by Heitmar, Rebekka et al.
Continuous Retinal Vessel Diameter Measurements:
The Future in Retinal Vessel Assessment?
Rebekka Heitmar,1 Andrew D. Blann,2 Robert P. Cubbidge,1 Gregory Y. H. Lip,1,2
and Doina Gherghel1
PURPOSE. To establish an alternative method, sequential and
diameter response analysis (SDRA), to determine dynamic ret-
inal vessel responses and their time course in serial stimulation
compared with the established method of averaged diameter
responses and standard static assessment.
METHODS. SDRA focuses on individual time and diameter re-
sponses, taking into account the fluctuation in baseline diam-
eter, providing improved insight into reaction patterns when
compared with established methods as delivered by retinal
vessel analyzer (RVA) software. SDRA patterns were developed
with measurements from 78 healthy nonsmokers and subse-
quently validated in a group of 21 otherwise healthy smokers.
Fundus photography and retinal vessel responses were as-
sessed by RVA, intraocular pressure by contact tonometry, and
blood pressure by sphygmomanometry.
RESULTS. Compared with the RVA software method, SDRA dem-
onstrated a marked difference in retinal vessel responses to
flickering light (P  0.05). As a validation of that finding, SDRA
showed a strong relation between baseline retinal vessel diam-
eter and subsequent dilatory response in both healthy subjects
and smokers (P  0.001). The RVA software was unable to
detect this difference or to find a difference in retinal vessel
arteriovenous ratio between smokers and nonsmokers (P 
0.243). However, SDRA revealed that smokers’ vessels showed
both an increased level of arterial baseline diameter fluctuation
before flicker stimulation (P  0.005) and an increased stiff-
ness of retinal arterioles (P  0.035) compared with those in
nonsmokers. These differences were unrelated to intraocular
pressure or systemic blood pressure.
CONCLUSIONS. SDRA shows promise as a tool for the assessment
of vessel physiology. Further studies are needed to explore its
application in patients with vascular diseases. (Invest Ophthal-
mol Vis Sci. 2010;51:5833–5839) DOI:10.1167/iovs.09-5136
The measurement of retinal vessel diameters is useful in theassessment and risk stratification of several cardiovascular
disorders.1,2 However, structural assessment offered by fundus
photography has several limitations. For example, static assess-
ment captures only a single image of the vascular system, and
so is unable to explore dynamic relationships and vascular
function. Furthermore, parameters commonly used for assess-
ment (such as the arteriolar narrowing) vary with age,3 and so
it is possible that other factors would also fluctuate. Alterna-
tively, dynamic retinal vessel assessment (also known as con-
tinuous retinal vessel diameter measurement) has been clini-
cally useful in several conditions, such as diabetes mellitus4,5
glaucoma,6 and in evaluating potential pathophysiological
mechanisms in the regulation of ocular blood flow.7–9
Several approaches are available for assessing dynamic ves-
sel diameter responses, as are different stimulation techniques.
The latter include flickering light,10 carbogen and oxygen
inhalation,8,11 and intravenous vasoactive substance infu-
sions.12,13 After stimulation with flickering light, retinal vessel
analyzer (RVA) software calculates maximum retinal vessel
response to 20 seconds of flickering light over three stimula-
tion cycles. The average responses within a 17- to 23-second
window after the start of the stimulation is taken to be the
maximum diameter response.4 This analysis generates a maxi-
mum artery dilatory response index (Amax), as well as similar
outputs for minimum response (Amin), peak response (Apeak),
and maximum venous dilatory response (Vmax) to flicker.
Analysis based on RVA software currently in practice anal-
yses retinal vascular responses to flicker in patients who have
various diseases. However, a major limitation of this averaging
approach is that it incorporates both time and diameter re-
sponses. For example, time responses fixed at 20 seconds may
be open to error, as subjects reaching maximum dilation be-
fore 17 seconds or later than 23 seconds after flicker initiation
may have their maximum dilatory response underestimated. In
addition, when results from all three stimulation cycles are
merged, differences in the reaction pattern or time course of
each cycle may result in lost significance. To assess differences
between cycles, others have incorporated an analysis of each
flicker cycle.14 A further problem in assessing maximum dila-
tory response to flicker light is of the baseline diameter fluc-
tuation (BDF) due to vascular tone and arterial pulsation. Nagel
et al.15 introduced the concept of baseline corrected flicker
response (BFR), where BDF is adjusted for the dilation ampli-
tude (DA) reached by flicker stimulation (i.e., BFR  DA 
BDF). However, this analysis does not examine each flicker
cycle separately. An additional problem is that of defining a
reaction pattern. To do so, the point of maximum dilation
(MD), the point of maximum constriction (MC), the DA, and
the time course of the reaction must all be determined. A
recently published report discussing these problems high-
lighted the need for a more advanced and in-depth analysis
incorporating both diameter and dilatory response.16
We propose a novel approach, which we have designated
sequential and diameter response analysis (SDRA), for the in-
vestigation of retinal vascular function by seeking to establish
a more cogent analytical methodology. SDRA was developed
after a comparison of the established retinal diameter assess-
ment method of static (AVR) and dynamic (Amax, Amin, Apeak,
and Vmax) measurements with a new group of measures (BFR,
DA, MD, and MC) and time course responses (see Fig. 1). We
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tested and validated SDRA in healthy volunteers and a group of
otherwise healthy but smoking individuals, who were likely to
exhibit vascular disturbances.
METHODS
Subjects
One hundred healthy smoking and nonsmoking individuals were re-
cruited. Smoking was identified by self-report (smoking on a regular
basis for at least 6 months before the study). Subjects were excluded if
they had an ocular refractive error of more than 3 D spherical power
and more than 1 D cylindrical power.16 This criterion was necessary
to address the magnification or minification that may cause over- or
underestimation of retinal diameter measured. Other exclusion criteria
were intraocular pressure (IOP) 24 mm Hg, the presence of cataract
or any other media opacities, a history of intraocular surgery, and any
form of retinal or neuro-ophthalmic disease affecting the ocular vascu-
lar system. Systolic and diastolic blood pressure (SBP/DBP) was mea-
sured by automated sphygmomanometry. Other exclusion criteria
were age 18 years, any history of systemic disease such as diabetes
mellitus, hypertension, or any vascular abnormalities such as Raynaud’s
syndrome, and any use of vasoactive drugs, anticoagulants, and lipid-
lowering agents. The study was approved by the Aston University
Ethics Committee. Written informed consent was received from all
subjects participating in the study. The study was designed and con-
ducted in accordance with the tenets of the Declaration of Helsinki. All
subjects were instructed to refrain from consuming caffeinated prod-
ucts, smoking, and drinking alcohol on the study day. Measurements
were performed between 12 noon and 2 PM on all subjects.
Procedures
For IOP determination, the subjects were seated for contact tonometry
according to standard practice, as per the manufacturer’s instructions
(TonopenXL; Medtronic Solan, PMS Instruments, Maidenhead, UK).
The probe was placed on the central aspect of the cornea. All mea-
surements were taken after topical instillation of 1 drop of 0.4%
benoxinate hydrochloride (Minims; Chauvin Pharmaceuticals, Bausch
and Lomb Ltd., Kingston-upon-Thames, UK). After an acclimatization
period of 15 to 20 minutes in a temperature-controlled room (22–
25°C), SBP, DBP, and heart rate were obtained by a validated medical
device (Digital BP Monitor UA-767EX-C; PMS Instruments). SBP and
DBP were measured three times at baseline (good clinical practice, as
recommended by the British Hypertension Society)17 before the start
of retinal vessel measurements and at 1-minute intervals during retinal
vessel assessment, to determine its potential influence on the param-
eters measured. All ocular and blood pressure measurements were
performed by a single operator (RH) registered with the General
Optical Council of the United Kingdom.
For retinal vessel diameter assessment, all measurements were
performed in one unselected eye from each subject. Continuous retinal
diameter assessment and fundus photography were obtained by RVA
and its inbuilt fundus camera (FF450; Carl Zeiss Meditec, GmbH, Jena,
Germany). Photography was performed on each patient (after full
dilation) with the angle set at 30° in black-and-white mode for highest
contrast. AVR was measured semiautomatically (VesselMap software;
Imedos GmbH, Jena, Germany).18
For RVA flicker measurement, the assessment of retinal vessel
diameter reaction to flickering light an optoelectronic shutter is in-
serted in the optical pathway of the camera, illuminating the retina.
Flicker is generated with the shutter by interrupting the observation
illumination to the fundus, producing a bright-to-dark contrast ratio of
at least 25:1. Rectangular light interruption of 12.5 Hz has been shown
to be in the range of maximum exciting flicker frequency.10 As video
frequency is set at 25 Hz, the flicker frequency will give one dark image
every second frame, translating into a sampling rate of 12.5 Hz during
flicker provocation. In the present study, we applied the protocol of
Nagel et al.19 After full pupil dilation was achieved (topical 0.5%
tropicamide; Minims; Chauvin Pharmaceuticals, Bausch & Lomb Ltd.)
flickering was commenced according to the pattern of a baseline
measurement of 50 seconds followed by three cycles of 20 seconds of
flickering and 80 seconds of recovery. Thus, total retinal assessment
lasted 350 seconds.
Sequential and Diameter Response Analysis
We collected standard AVR analysis data and the RVA software-generated
parameters Amax, Amin, Apeak, and Vmax and used the raw data to gener-
FIGURE 1. The retinal diameter re-
sponse to flicker provocation. Illus-
trated are changes in a retinal vessel
as it is stimulated by flickering light.
On the far left, BDF defines the fluc-
tuation in the baseline diameter. The
central section shows an increase in
relative vessel diameter due to flick-
ering light. This response provides
the MD, the DA, and the time to
reach MD. The right side shows the
responses of the vessel as it recovers
(no data collected).
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ate an SDRA taking each of the three individual flicker cycles into
account. Our approach to SDRA focuses on three steps. First, to more
accurately assess dilatory responses, in addition to the calculation of
MD, MC, and DA, we investigated the time course of retinal vascular
dilation by calculating the time needed to reach MD for each flicker
cycle separately in both the selected artery and vein. Second, to
determine any effect that the baseline variability in vessel diameter
might have, we derived a new index, D, representing the degree of
vessel dilation occurring between the flicker initiation and vascular
MD (i.e., D  MD  the mean diameter of the particular vessel
assessed in a 1-second time period before flickering commences). In
this way, D shows the remaining dilatory capacity after flicker initi-
ation. Third, to assess the relative stiffness of the measured retinal
arteriole, we defined a second new index by calculating the ratio
between the BDF before stimulation with flickering light and the DA
after provocation; we term this index the average peak ratio (APR) and
use it as a measure of retinal arteriolar elasticity (i.e., APR  DA/BDF).
Plan of Validation
To validate the SDRA, we assessed basic demographic (age and sex in
all participants) and anatomic (left or right eye in a representative
subgroup) indices so as to address these possible confounders in
subsequent analyses (e.g., smoking).
Statistical Analyses
Differences between two groups were analyzed either by using the
Mann-Whitney U test or t-test, depending on distribution. Differences
within a group were assessed by paired t tests. If non-normally distrib-
uted, the data were log transformed. In other cases, differences were
sought by repeated measurements ANOVA or Friedman’s method,
followed by Tukey’s post hoc test. Data correlations were determined
according to Spearman’s method. Relationships between age, dynamic
response values to flicker light provocation, and changes in vessel
diameter were sought using multivariate regression analyses. Statistical
significance was defined at the level of P  0.05. When computing
multiple comparisons, we set the significance level at P  0.01 to
minimize bias (all analyses performed with Statistica ver. 6.0; Statsoft,
Tusla, OK).
RESULTS
Patient Demographics and Basic Vessel Indices
Age, sex, and blood pressure indices of the nonsmokers and
smokers are shown in Table 1. In the smokers, cigarette usage
per day ranged from 5 to 15 (mean  SD, 9  3), and the
duration of smoking varied between 3 and 20 years (smoking
history: 10  5 years). There were no statistically significant
differences between the 21 smokers and the 21 nonsmokers
(selected to be age and sex matched to the smokers) at baseline
with regard to IOP, SBP, DBP, mean arterial pressure (MAP)
and retinal arteriolar vascular diameter, although venous diam-
eter was higher in smokers. In a regression analysis, age, sex,
and BP indices had no impact on the retinal vessel parameters
in the nonsmokers.
SDRA: Impact of Age, Sex, and Left/Right Eye
We developed SDRA using data from 78 healthy, nonsmoking
individuals. Coefficients of variation (CV) of the effect of flick-
ers were determined by analyzing data from three flicker cycles
in each of the 78 subjects. In the arteries, mean (SD) CVs were
1.3% (1.1%) for MD, 1.2% (0.9%) for MC, and 31.5% (19.3%) for
reaction time (RT). In the veins, parallel data were 1.0% (0.8%),
0.8% (0.6%), and 17.9% (12.7%). In regard to vessel responses
to flickering light, the mean (SD) MD, MC, and RT of 78 arteries
were 4.9% (2.2%), 3.2% (1.8%%), and 16.1 (4.1) seconds,
respectively. In veins, parallel data were 5.9% (2.2%) (P 
0.008 vs. arteries), 1.3% (1.0) (P  0.001), and 19.4 (2.8)
seconds (P  0.001), respectively.
Correlation coefficients of age with MD, MC, and RT in
arteries were r  0.1 (P  0.393), r  0.31 (P  0.008), and
r  0.12 (P  0.301), respectively. In veins, parallel data were
r  0.12 (P  0.300), r  0.02 (P  0.854), and r  0.13
(P  0.320). The correlation coefficients of age with CVs of
MD, MC, and RT of arteries were r  0.16 (P  0.162), r 
0.08 (P  0.478), and r  0.15 (P  0.199). In veins, parallel
data were r  0.12 (P  0.316), r  0.04 (P  0.723), and
r  0.05 (P  0.637), respectively. We conclude that, using
SDRA, the MD, MC, or RT of arteries or veins, or their CVs, are
not influenced markedly by age, with the exception of the
arterial MC.
The SRDA parameters BDF, MD, MC, DA, and the reaction
time to reach MD in arteries and veins between 45 male and 33
female subjects are as follows: Arterial BDF (%) was 4.04 (1.66)
and 4.30 (2.18), respectively (P  0.890). Similarly, MD (%)
was 5.23 (2.59) and 4.64 (2.22) (P 0.432), MC (%) was3.07
(1.68) and 3.38 (2.07; P  0.607), DA (%) was 8.29 (2.84)
and 8.01 (3.37; P  0.636), and RT (seconds) was 16.3 (4.0)
and 15.8 (4.2) (P  0.559). Venous responses were MD (%)
5.57 (1.94) and 6.22 (2.28) (P  0.238), MC (%) 1.15 (0.86)
and 1.36 (1.26) (P  0.755), DA (%) 6.71 (2.27) and 7.58
(3.13) (P  0.334), and RT (seconds) was 19.2 (2.8) and 19.4
(3.1) (P  0.607). Paired right and left eye measurements (n 
33) were compared in a subset of subjects as follows: Arterial
BDF (%) was 4.03 (1.63) and 4.35 (2.24) (P  0.706), MD (%)
was 4.97 (2.23) and 4.84 (2.32) (P 0.540), MC (%) was2.75
(1.78) and 3.55 (1.85) (P  0.074), DA (%) was 7.72 (2.86)
and 8.68 (3.19) (P  0.244), and RT (seconds) was 15.8 (3.9)
and 16.5 (4.2) (P  0.487). Venous responses were MD (%)
5.77 (2.03) and 6.04 (2.33) (P  0.704), MC (%) was 0.99
(0.93) and1.5 (1.20) (P 0.083), DA (%) was 6.76 (2.35) and
7.57 (3.13) (P  0.259), and RT (seconds) was 19.0 (2.9) and
19.7 (2.8) (P  0.652).
A strength of the SDRA is that it can obtain improved insight
into the mechanisms that determine the amount of vascular
dilation due to flickering-light stimulation in retinal vessels. For
example, SDRA can be used to assess the relationship between
the mean diameter measured in the 1-second period directly
before the start of flicker stimulation with D. The arterial MD
reached due to flicker stimulation correlated inversely with its
prestimulation diameter, as assessed for each of the three
flicker cycles (cycle one: r  0.40, P  0.001; cycle two: r 
0.31, P  0.009; cycle three: r  0.26, P  0.029). Simi-
larly, there was a significant relationship between the individ-
ual venous baseline diameters and D for each cycle, although
this change was weaker and reached significance only in the
TABLE 1. Demographic and Vascular Data
Parameter
Nonsmoker
(n  78)
Nonsmoker
Subset
(n  21)
Smoker
Subset
(n  21) P
Age, y 36 (14) 27 (6) 31 (10) 0.202
Sex, M/F 45/33 8/13 8/13 1.000*
IOP, mmHg 14 (3) 14 (3) 15 (2) 0.618
SBP, mmHg 120 (12) 117 (12) 112 (10) 0.165
DBP, mmHg 74 (9) 72 (9) 71 (9) 0.561
MAP, mmHg 89 (9) 87 (9) 85 (9) 0.282
Size, A (m) 120 (20) 120 (20) 122 (15) 0.842
Size, V (m) 150 (18) 150 (16) 161 (16) 0.018
Data presented as mean (standard deviation) or actual number. P
values by t-test or *2 test. SBP, systemic blood pressure; DBP, diastolic
blood pressure; MAP, mean arterial pressure; Size (A), arterial diameter,
Size (V), venous diameter.
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first two cycles (cycle one: r  0.26, P  0.032; cycle two:
r  0.34, P  0.004; cycle three: r  0.19, P  0.112).
Comparing SDRA and Dynamic Retinal
Diameter Evaluation
To support our hypothesis that inbuilt RVA software underes-
timates retinal artery and vein dilation in subjects reacting
faster than 17 seconds or slower than 23 seconds, we com-
pared both established (RVA) and novel (SDRA) parameters in
healthy nonsmokers. Subjects were divided into three groups:
Group 1 reached MD within 17 seconds after flicker initiation,
group 2 reached MD within 17 to 23 seconds, and group 3
reached MD after 23 seconds14 (Table 2).
Of the 78 subjects, 52 reached arterial MD before 17 sec-
onds (mean (SD) arterial reaction time: 13.7 (2.2) seconds), 23
subjects reached MD within 17 to 23 seconds (mean reaction
time of 19.7 (1.2) seconds), whereas the remaining three
reached MD beyond 23 seconds (average arterial reaction time:
27.3 (1.2) seconds). These data were markedly different from the
presumption that all 78 subjects would have reached MD within
17 to 23 seconds (P 0.001). Similarly, the frequency of subjects
whose venous MD were in one of the three groups was n  16,
n  54, and n  8, respectively, for 17 seconds, 17 to 23
seconds, and23 seconds. This frequency also differed markedly
from a presumed distribution of 0, 78, and 0, respectively, accord-
ing to the traditional definition (P  0.001).
The frequency of arterial responses (45, 23, and 7) differed
markedly from the frequency of venous responses (16, 54, and
8) (P  0.001): Actual mean (SD) reaction times in arteries and
veins were 16.1 (4.1) and 19.4 (2.8) seconds, respectively (P
0.001). Other analyses for Amax, Amin, Apeak, and Vmax for
arterial and venous responses are shown in Table 2 and once
more, there are several significant differences in both vessel
responses between the data delivered by the RVA software and
data delivered by SDRA. We conclude from this section that the
underlying assumption that both arteries and veins reach MD
within 17 to 23 seconds is fundamentally flawed.
Validating SDRA in a Pathologic Setting
We validated SDRA by comparing retinal vessel responses to
flicker light in 21 healthy subjects with 21 age- and sex-
matched subjects likely to have minor vascular disease by
virtue of smoking (Table 1). Table 3 shows that there are no
significant differences between arterial and venous MD, MC,
and RT, or their CVs and age, except a weak relationship
between age and arterial MD in smokers. Table 4 shows dila-
tory responses of retinal arteries and veins in smokers and
nonsmokers. Significant differences in arterial responses were
present in regard to DA and for the BFR in the first flicker cycle
alone: Responses were higher in smokers. In health, the BFR did
not change with repeated stimulation. However, in smokers,
arterial BFR (a measurement that takes into account the arterial
pulse) was markedly lower at the second and third stimulation
cycles when compared with the first cycle (P  0.048). There
were no significant differences in the venous parameters.
Table 5 shows that there were no significant differences
between smokers and nonsmokers in mean reaction time in
either retinal arteries or veins, according to the SRDA. Table 6
shows traditional retinal vessel analysis using AVR along with
TABLE 2. Retinal Artery and Vein Dilatory Responses:
Comparison between Analysis Methods
Parameter (n) RVA Software SDRA P
Arterial response
Amax (%)
Group 1 (52) 2.83 (2.00) 4.66 (2.20) 0.0001
Group 2 (23) 4.30 (2.18) 5.40 (2.49) 0.0001
Group 3 (3) 2.13 (0.57) 5.30 (0.71) 0.108*
Amin (%)
Group 1 (52) 0.77 (1.43) 3.59 (1.92) 0.0001
Group 2 (23) 0.66 (1.45) 2.53 (1.46) 0.0001
Group 3 (3) 0.67 (0.40) 2.62 (1.43) 0.109*
Apeak (%)
Group 1 (45) 3.58 (2.55) 8.25 (3.17) 0.0001
Group 2 (23) 4.94 (2.56) 7.93 (2.79) 0.0001
Group 3 (3) 2.86 (0.84) 7.92 (2.13) 0.109*
Venous response
Vmax (%)
Group 1 (16) 4.32 (1.98) 5.56 (2.08) 0.0001
Group 2 (54) 4.93 (1.84) 6.00 (2.12) 0.0001
Group 3 (8) 2.65 (2.37) 4.76 (1.91) 0.0277*
Data are expressed as the mean (standard deviation). Comparison
of retinal arterial and venous dilatory responses as calculated by RVA
software and SDRA. Values are expressed as % changes. Group 1,
reaction time 17 seconds; group 2, reaction time 17  RT 23
seconds; group 3, reaction time 23 seconds.
* Data acknowledged to be nonsignificant as a result only of small
sample size.
TABLE 3. Correlation between Dynamic Retinal Vessel Parameters and Age Using SRDA
Parameter
Nonsmokers (n  21) Smokers (n  21)
Raw Data Correlation (r, P) Raw Data Correlation (r, P)
Arteries
MD (%) 4.94 (2.42) (0.07, 0.752) 6.14 (2.78) (0.43, 0.048)
MD (CV) 1.3 (0.7) (0.22, 0.316) 1.7 (1.9) (0.06, 0.806)
MC (%) 3.23 (1.87) (0.37, 0.098) 4.22 (2.16) (0.30, 0.183)
MC (CV) 1.2 (0.6) (0.08, 0.716) 1.4 (1.5) 0.04, 0.861
RT (s) 15.1 (3.5) (0.13, 0.569) 15.4 (4.9) (0.02, 0.945)
RT (CV) 30.6 (19.1) (0.27, 0.231) 37.8 (20.8) (0.02, 0.930)
Veins
MD (%) 5.89 (2.05) (0.08, 0.688) 6.81 (2.49) (0.41, 0.062)
MD (CV) 1.0 (0.6) (0.12, 0.578) 1.4 (0.9) (0.24, 0.290)
MC (%) 1.26 (1.53) (0.05, 0.798) 1.50 (0.87) (0.06, 0.804)
MC (CV) 0.6 (0.3) (0.19, 0.399) 0.8 (0.4) (0.16, 0.487)
RT (s) 19.5 (2.8) (0.42, 0.057) 19.2 (3.4) (0.11, 0.646)
RT (CV) 18.6 (9.4) (0.50, 0.018) 18.4 (12.3) (0.41, 0.060)
Data are the retinal artery and venous responses and their relationship with age (bold denotes
significant results).
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the software’s own data analysis of dynamic retinal vessel
response to flickering light in arteries and veins. There were no
differences between smokers and nonsmokers.
Examination of retinal arteriolar elasticity (as defined by the
ratio of DA divided by BDF) in healthy eyes showed no signif-
icant difference in the mean (SD) ratio between the three
flicker light cycles: cycle 1, 2.21 (1.10); cycle 2, 2.18 (0.92);
and cycle 3, 2.43 (1.22) (P 0.343). However, in smokers, the
ratio decreased from the first to the third cycle: cycle 1, 2.43
(0.94); cycle 2, 1.92 (0.83); and cycle 3, 1.81 (0.69) (P 
0.022).
DISCUSSION
The current approach to the analysis of intraocular blood
vessel responses to flicker light is attractive as it is technolog-
ically simple and noninvasive, but it has several drawbacks. In
the present study, we addressed these questions by assessing
the retinal vasculature at baseline and during flickering-light
stimulation. The response of retinal vessels to flickering-light
stimulation and its relationship to age and sex and to right and
left eye and baseline retinal diameter was evaluated in healthy
nonsmokers. Testing the applicability and importance of clin-
ical assessment in vascular disease was determined in a sample
of regular cigarette smokers who otherwise had no apparent
ocular and vascular disease.
We have presented technical and validation data of our
novel analytical method, SDRA, which has good coefficients of
variation. Although response time is variable in arteries and
veins, this is less relevant as we have analyzed each flicker
response individually. We have demonstrated that dynamic
retinal responses in arteries and veins are independent of age,
sex, and right/left eye, and that arterial reaction to flicker light
stimulation is faster but less pronounced than venous re-
sponses. The assumption of the RVA software analysis that
arteries and veins react at the same speed10 therefore should
be re-evaluated. SDRA showed marked differences in individual
reaction times (based on the 17–23 second model) which the
traditional method is unable to address. We find that the tradi-
tional method underestimates retinal arterial and venous dila-
tory responses—that is, that SDRA is more sensitive.
The vascular system degrades with age, and there can be
increased development of vessel disease.20,21 At the retinal
level, age-related changes such as arteriolar narrowing and loss
of reflex can be readily observed noninvasively by ophthalmos-
copy and fundus photography.22,23 Previous studies using
static assessments have reported age to be associated with
structural retinal venular dilation in smokers,24 possibly relat-
ing chronic smoking to premature aging of the vascular system.
Using SDRA, we were unable find an association between
dynamic retinal parameters (and their CVs) and the age of the
subject. However, we found that MC increased with age. The
loss of reflex with age could explain this finding, since all
dimension measurements are based on contrast levels, which
TABLE 4. Retinal Arterial and Venous Dilatory Parameters to
Flickering-Light Stimulation
Parameter
Nonsmoker
(n  21)
Smoker
(n  21) P
Arterial response
BDF (%)
Flicker 1 4.79 (2.66) 5.04 (2.63) 0.769
Flicker 2 4.69 (2.75) 6.05 (3.10) 0.141
Flicker 3 4.65 (3.25) 5.95 (2.21) 0.142
Friedman ANOVA
(within group) 0.879 0.067
DA (%)
Flicker 1 8.17 (3.77) 10.69 (2.94) 0.020
Flicker 2 8.25 (3.57) 10.26 (3.96) 0.092
Flicker 3 8.08 (3.73) 10.14 (4.04) 0.098
Friedman ANOVA
(within group) 0.915 0.467
BFR (%)
Flicker 1 3.37 (2.74) 5.65 (2.11) 0.004
Flicker 2 3.55 (2.96) 4.21 (3.22) 0.501
Flicker 3 3.52 (2.74) 4.20 (3.54) 0.501
Friedman ANOVA
(within group) 0.818 0.048
Venous response
MD (%)
Flicker 1 5.80 (2.57) 6.60 (3.15) 0.382
Flicker 2 6.09 (2.11) 7.08 (2.60) 0.184
Flicker 3 5.86 (2.25) 6.56 (2.84) 0.398
Friedman ANOVA
(within group) 0.691 0.580
MC (%)
Flicker 1 1.66 (1.85) 1.37 (1.24) 0.709
Flicker 2 1.10 (1.54) 1.71 (1.29) 0.173
Flicker 3 1.30 (1.50) 1.32 (0.86) 0.944
Friedman ANOVA
(within group) 0.513 0.861
DA (%)
Flicker 1 7.41 (3.98) 7.98 (3.04) 0.609
Flicker 2 7.19 (3.25) 8.79 (2.84) 0.097
Flicker 3 7.16 (3.46) 7.88 (3.19) 0.498
Friedman ANOVA
(within group) 0.945 0.212
Data are expressed as the mean  SD retinal arterial and venous
dilatory parameters for all three flicker cycles (bold denotes significant
results). All relative values are expressed as percent changes in baseline
diameter.
TABLE 5. Retinal Arterial and Venous Reaction Time to
Flickering-Light Stimulation, according to SDRA
Parameter
Nonsmoker
(n  21)
Smoker
(n  21) P
Arterial response, s
Flicker 1 15.0 (5.3) 13.8 (7.7) 0.570
Flicker 2 15.5 (4.3) 17.1 (7.0) 0.387
Flicker 3 14.8 (5.7) 15.6 (5.2) 0.526
Friedman ANOVA
(within group)
0.906 0.559
Venous response, s
Flicker 1 19.6 (3.4) 19.7 (4.1) 0.955
Flicker 2 19.1 (4.3) 18.5 (5.1) 0.697
Flicker 3 20.1 (4.6) 19.3 (4.3) 0.526
Friedman ANOVA
(within group)
0.681 0.434
Data are expressed as the mean (standard deviation), reaction time
for all three flicker cycles of retinal veins and arteries in nonsmokers
and smokers.
TABLE 6. AVR and RVA Software-Generated Analysis
Parameter
Nonsmoker
(n  21)
Smoker
(n  21) P
AVR 0.81 (0.12) 0.77 (0.12) 0.243
Amax, % 3.47 (2.34) 3.51 (2.21) 0.921
Amin, % 0.32 (1.48) 0.66 (1.91) 0.485
Apeak, % 3.81 (2.82) 4.37 (2.56) 0.330
Vmax, % 4.65 (1.72) 4.90 (2.60) 0.881
Data are expressed as the mean SD. Static retinal vessel data and
the software- generated output. All relative values expressed as percent
changes compared with baseline diameters.
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can be expected to be decreased with age. However, if MC is
age dependent, one would expect the CV of MC to be in-
creased in parallel, which was not the case.
In the large sample of 78 nonsmokers, SDRA showed a
significant correlation between each baseline diameter and its
corresponding dilatory response in all three flicker stimulation
cycles in retinal arteries and the first two stimulation cycles in
retinal veins. On the basis of this result, we conclude that
retinal vessels have a fixed dilatory capacity: the baseline di-
ameter is a strong predictor of the ultimate vessel dilation and
must therefore be considered in analysis.
Smoking is the primary risk factor for both CAD and periph-
eral artery disease (PAD) and causes vascular disease.25–27 The
traditional methods of static retinal imaging and the RVA soft-
ware analysis were unable to detect any differences in retinal
vessel responses in smokers and nonsmokers. However, de-
spite the small sample (n  21/group), SDRA detected differ-
ences in arterial DA, BFR, and elasticity between these groups;
there was no difference in venous responses. In the present
study, we confirm and extend findings in other studies,28,29 as
we found that smokers had significantly larger retinal venular
diameter compared with healthy, nonsmoking control individ-
uals, and we presume that this finding is due to smoking.
However, as there were no differences in functional vein re-
sponses, the pathophysiological significance of our finding that
smokers’ venules have a larger diameter (perhaps reflecting
structural changes) is unclear. Our data also confirm a report30
that neither SBP nor DBP has any influence on retinal vascular
reactivity.
In arteries, when the BDF was taken into account and the
pure reaction to flicker light stimulation was compared be-
tween smokers and healthy nonsmokers, a significant differ-
ence was apparent only for the first stimulation cycle. It could
be hypothesized that diffuse endothelial impairment and de-
creased bioavailability of NO associated with chronic smoking
may have had an exhaustive effect on vessels reactivity and
elasticity and may reflect a change in microvascular function at
the retinal level in smokers that could be the result of a
disequilibrium between endothelial vasodilatory and vasocon-
strictive molecules.31,32
The static assessment of retinal vessels is a powerful tech-
nique for assessing vascular physiology and disease.1–3 SDRA
extends these techniques by examining dynamic changes and
indicates that the diameter analysis, as provided by the RVA
software, has the tendency to underestimate the dilatory re-
sponse released by flicker stimulation. In addition, unlike the
dynamic method, static retinal vessel evaluation was not able
to detect differences between healthy subjects and cigarette
smokers. We speculate that SDRA will also detect differences
in vascular responses in other conditions such as diabetes and
cardiovascular disease.
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